por
Sean Ruck, Contributing Editor | June 23, 2015
From the June 2015 issue of HealthCare Business News magazine
HCBN: Are there any recent advancements in nuclear cardiology you’re especially excited about?
DW: Many of the things I have mentioned are cutting edge; we are excited about implementing them. There are new cameras that allow us to get far more information and better quality images. They have tremendous potential for research. PET is growing with new agents that may allow for new protocols. In the future we will have molecular imaging that will begin to identify disease at a very early stage. We’re also beginning to be disease-specific in our technology. These are all new areas where we believe there will be high visibility of nuclear cardiology, but we have to prove quality not just in a silo, but how it affects medicine as a whole.
HCBN: How do you think the nuclear cardiology field will have changed 10 years from now?
Ad Statistics
Times Displayed: 14290
Times Visited: 25 Final days to save an extra 10% on Imaging, Ultrasound, and Biomed parts web prices.* Unlimited use now through September 30 with code AANIV10 (*certain restrictions apply)
DW: If you look at the evolution of nuclear cardiology, like any diagnostic test, once you’ve proved it is accurate the next question you should ask, from a prognostic point of view, is does it change my treatment? That’s a big question. It’s a risk assessment. One way to look at risk assessment - if you’re standing on your porch step, there’s not much risk in jumping down, but if you’re standing on the edge of the pool, how deep is it? Can you swim? Can you get out? Can you get out the other end? That’s the risk assessment. We’ll need to have nuclear cardiology as something that can guide therapy. Patients will need to be tested less often, and fewer will be tested, but there’s probably going to be better determinations on who needs to be tested and what the best test is and what the best treatment is for them.
Back to HCB News
